Duality Biotherapeutics, Inc. (HK:9606)
:9606
Top Page
Duality Biotherapeutics, Inc.
(9606)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$325.00
▲(7.19% Upside)
Action:ReiteratedDate:11/14/25
The overall stock score of 46 for Duality Biotherapeutics reflects significant financial risks as the primary concern, with negative profitability and equity overshadowing strong revenue growth. Technical analysis suggests a neutral stance with mixed momentum, while valuation remains inconclusive due to missing data. Investors should approach with caution given the financial weaknesses.
Positive Factors
Revenue Growth
The substantial revenue growth indicates strong market demand and successful execution of strategic initiatives, enhancing long-term business prospects.
Negative Factors
Financial Instability
High leverage and negative equity can limit financial flexibility and increase risk, potentially impacting long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The substantial revenue growth indicates strong market demand and successful execution of strategic initiatives, enhancing long-term business prospects.
Read all positive factors
Duality Biotherapeutics, Inc. (9606) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$27.33B
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees170
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding90,137,710
10 Day Avg. Volume2,424,103
30 Day Avg. Volume1,602,164
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-7.92
Price to Sales (P/S)8.25
P/FCF Ratio62.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$443.08Price Target Upside46.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Duality Biotherapeutics, Inc. Business Overview & Revenue Model
Company Description
Duality Biotherapeutics, Inc. operates as a clinical stage company. It focuses on the development of next generation antibody-drug conjugate therapeutics and duality immune toxin antibody conjugate therapeutic. The company was founded by Zhu Zhong...
How the Company Makes Money
Duality Biotherapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model includes income from partnerships and collaborations with larger pharmaceutical companies, w...
Duality Biotherapeutics, Inc. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
20
Very Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 1.71B | 1.94B | 1.79B | 1.60M |
| Gross Profit | 714.52M | 784.67M | 1.36B | 1.60M |
| EBITDA | -353.67M | -1.01B | -197.07M | -385.22M |
| Net Income | -2.56B | -1.05B | -357.51M | -387.09M |
Balance Sheet | ||||
| Total Assets | 4.18B | 2.09B | 1.50B | 463.74M |
| Cash, Cash Equivalents and Short-Term Investments | 3.70B | 1.39B | 1.13B | 375.97M |
| Total Debt | 67.89M | 5.29M | 5.32M | 4.67M |
| Total Liabilities | 1.26B | 4.11B | 2.62B | 1.23B |
| Stockholders Equity | 2.91B | -2.02B | -1.12B | -769.12M |
Cash Flow | ||||
| Free Cash Flow | 845.06M | 254.60M | 780.43M | -321.67M |
| Operating Cash Flow | 855.12M | 285.78M | 816.34M | -299.47M |
| Investing Cash Flow | -651.24M | -211.15M | -78.55M | -22.20M |
| Financing Cash Flow | 1.73B | -7.62M | 10.82M | 451.46M |
Duality Biotherapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$6.57B | 7.50 | 14.79% | 2.61% | 16.41% | 32.97% | |
66 Neutral | HK$14.00B | 45.44 | 4.98% | ― | ― | ― | |
58 Neutral | HK$9.69B | 14.45 | 5.62% | 4.47% | 1.65% | -16.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.11B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
46 Neutral | HK$27.33B | -6.90 | -443.72% | ― | ― | ― | |
41 Neutral | HK$713.80M | -3.66 | -9.19% | ― | -30.60% | 28.61% |
* Healthcare Sector Average
HK:9606
Duality Biotherapeutics, Inc.
303.20
116.00
61.97%
HK:2142
HBM Holdings Ltd.
13.69
7.22
111.59%
HK:2216
Broncus Holding Corp.
1.35
0.36
36.36%
HK:2273
Gushengtang Holdings Limited
28.04
-1.68
-5.65%
HK:6699
Angelalign Technology Inc.
81.95
34.14
71.41%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.36
1.24
24.12%
Duality Biotherapeutics, Inc. Corporate Events
Duality Biotherapeutics Shareholders Approve 2025 Equity Incentive Scheme and Mandate Limits
Dec 30, 2025
Duality Biotherapeutics shareholders have approved the company’s new 2025 Share Scheme at an extraordinary general meeting held on 30 December 2025, passing all three ordinary resolutions by a clear majority via poll. The resolutions authori...
Duality Biotherapeutics Proposes 2025 Share Scheme to Boost Growth
Dec 14, 2025
Duality Biotherapeutics, Inc. has announced its proposal to adopt the 2025 Share Scheme, which aims to attract and retain key participants crucial to the company’s long-term growth. The scheme is designed to recognize and reward contribution...
Duality Biotherapeutics Announces EGM for 2025 Share Scheme Approval
Dec 14, 2025
Duality Biotherapeutics, Inc. has announced an extraordinary general meeting to be held on December 30, 2025, to discuss and potentially approve the 2025 Share Scheme. This scheme involves resolutions for the allotment and issuance of shares under...
Duality Biotherapeutics Announces Extraordinary General Meeting
Dec 8, 2025
Duality Biotherapeutics, Inc. has announced the scheduling of an extraordinary general meeting (EGM) to be held on December 30, 2025, in Shanghai, China. The meeting will determine the identity of shareholders eligible to attend and vote, with a b...
Duality Biotherapeutics Plans RMB Share Listing on Shanghai’s Sci-Tech Board
Oct 17, 2025
Duality Biotherapeutics, Inc. has announced a proposal to issue ordinary shares in Renminbi to be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. This proposed issuance is contingent upon market conditions, bo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.